BridgeBio Pharma Inc. (BBIO)
BridgeBio Pharma Statistics
Share Statistics
BridgeBio Pharma has 188.99M shares outstanding. The number of shares has increased by 2.46% in one year.
| Shares Outstanding | 188.99M |
| Shares Change (YoY) | 2.46% |
| Shares Change (QoQ) | 0.51% |
| Owned by Institutions (%) | 90.83% |
| Shares Floating | 147.44M |
| Failed to Deliver (FTD) Shares | 61 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 20.38M, so 10.79% of the outstanding shares have been sold short.
| Short Interest | 20.38M |
| Short % of Shares Out | 10.79% |
| Short % of Float | 13.79% |
| Short Ratio (days to cover) | 8.07 |
Valuation Ratios
The PE ratio is -10.22 and the forward PE ratio is -10.23. BridgeBio Pharma 's PEG ratio is -0.57.
| PE Ratio | -10.22 |
| Forward PE | -10.23 |
| PS Ratio | 706.43 |
| Forward PS | 3.9 |
| PB Ratio | -4.85 |
| P/FCF Ratio | -12.42 |
| PEG Ratio | -0.57 |
Enterprise Valuation
BridgeBio Pharma Inc. has an Enterprise Value (EV) of 7.94B.
| EV / Earnings | -12.34 |
| EV / Sales | 853.04 |
| EV / EBITDA | -14.03 |
| EV / EBIT | -13.07 |
| EV / FCF | -15 |
Financial Position
The company has a current ratio of 3.32, with a Debt / Equity ratio of -1.28.
| Current Ratio | 3.32 |
| Quick Ratio | 3.32 |
| Debt / Equity | -1.28 |
| Total Debt / Capitalization | 451.23 |
| Cash Flow / Debt | -0.3 |
| Interest Coverage | -7.47 |
Financial Efficiency
Return on equity (ROE) is 0.47% and return on capital (ROIC) is -152.87%.
| Return on Equity (ROE) | 0.47% |
| Return on Assets (ROA) | -1.18% |
| Return on Capital (ROIC) | -152.87% |
| Revenue Per Employee | 16.91K |
| Profits Per Employee | -1.17M |
| Employee Count | 550 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 7.61% in the last 52 weeks. The beta is 1.07, so BridgeBio Pharma 's price volatility has been higher than the market average.
| Beta | 1.07 |
| 52-Week Price Change | 7.61% |
| 50-Day Moving Average | 31.31 |
| 200-Day Moving Average | 27.55 |
| Relative Strength Index (RSI) | 62.22 |
| Average Volume (20 Days) | 2.59M |
Income Statement
In the last 12 months, BridgeBio Pharma had revenue of 9.30M and earned -643.20M in profits. Earnings per share was -3.95.
| Revenue | 9.30M |
| Gross Profit | 6.86M |
| Operating Income | -607.37M |
| Net Income | -643.20M |
| EBITDA | -565.47M |
| EBIT | -607.37M |
| Earnings Per Share (EPS) | -3.95 |
Balance Sheet
The company has 375.94M in cash and 1.74B in debt, giving a net cash position of -1.36B.
| Cash & Cash Equivalents | 375.94M |
| Total Debt | 1.74B |
| Net Cash | -1.36B |
| Retained Earnings | -2.56B |
| Total Assets | 664.98M |
| Working Capital | 305.36M |
Cash Flow
In the last 12 months, operating cash flow was -527.72M and capital expenditures -1.31M, giving a free cash flow of -529.03M.
| Operating Cash Flow | -527.72M |
| Capital Expenditures | -1.31M |
| Free Cash Flow | -529.03M |
| FCF Per Share | -3.25 |
Margins
Gross margin is 73.71%, with operating and profit margins of -6.53K% and -6.91K%.
| Gross Margin | 73.71% |
| Operating Margin | -6.53K% |
| Pretax Margin | -7.02K% |
| Profit Margin | -6.91K% |
| EBITDA Margin | -6.08K% |
| EBIT Margin | -6.53K% |
| FCF Margin | -5.69K% |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.75% |
| FCF Yield | -7.61% |
Analyst Forecast
The average price target for BBIO is $46.5, which is 26.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $46.5 |
| Price Target Difference | 26.5% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Scores
| Altman Z-Score | -4.66 |
| Piotroski F-Score | 2 |